A Randomized, Double-blind, Parallel Group,Controlled Study to Compare the Immunogenicity and Safety of MSB11455 and Neulasta in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2019
Price : $35 *
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Cancer
- Focus Pharmacodynamics
- Sponsors Fresenius Kabi; Merck KGaA
- 19 Mar 2019 Status changed from active, no longer recruiting to completed.
- 09 Oct 2018 According to a Fresenius Kabi media release, primary endpoint (to Assess the Immunogenicity of MSB11455 Compared to Neulasta) has been met.
- 07 Dec 2017 Status changed from recruiting to active, no longer recruiting.